| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Ivan Chen last filed a Form 4 in August 2024, as Director at PURE. Ivan Chen's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 750,000 shares of PURE. Net of sales, the PURE filings show accumulation of 100,000 shares.
Ivan Chen has 10 Form 4 filings on record from June 2018 to August 2024, all as Director at Pure Bioscience (PURE), 2018–2024.
The 11 reported transactions were 7 option or other derivative awards, 3 stock awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $35K and no sales.
The only open-market purchase was 100,000 shares of PURE at an average $0.35 on May 9, 2019, about $35K.
Shares as reported in the last Form 4 for each company; the most recent is from August 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 9, 2019 | PURE Pure Bioscience, Inc. | Director | Buy | 100,000 | $0.35 | $35,000.00 | +66.7% |